Clinical pharmacology of emicizumab for the treatment of hemophilia A.

Koichiro YoneyamaChristophe SchmittAgnès PortronAnna KiialainenNaoki KotaniFelix JaminionSylvie RetoutJoanne I Adamkewicz

Published in: Expert review of clinical pharmacology (2023)

The translation of emicizumab PK/PD into clinical effects was demonstrated in several phase III studies, which showed remarkable bleed control and a favorable safety profile in PwHA. These emicizumab attributes, together with the convenience of use (infrequent SC injections), offer a novel paradigm for the management of PwHA.

Keyphrases

phase iii
open label
clinical trial
double blind
phase ii
case control
study protocol
smoking cessation